- Home
- NXL vs BLRX Comparison
NXL vs BLRX Comparison
Compare NXL & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NXL | BLRX |
|---|---|---|
| Founded | 2010 | 2003 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.6M | 12.6M |
| IPO Year | 2022 | 2010 |
Fundamental Metrics
Financial Performance| Metric | NXL | BLRX |
|---|---|---|
| Price | $0.37 | $2.75 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $19.00 |
| AVG Volume (30 Days) | ★ 220.5K | 8.1K |
| Earning Date | 05-11-2026 | 05-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 39.76 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $301,647.00 | N/A |
| Revenue This Year | $15.52 | N/A |
| Revenue Next Year | $100.00 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 78.78 | N/A |
| 52 Week Low | $0.31 | $2.15 |
| 52 Week High | $2.00 | $4.56 |
Technical Indicators
Market Signals| Indicator | NXL | BLRX |
|---|---|---|
| Relative Strength Index (RSI) | 44.54 | 41.00 |
| Support Level | $0.34 | $2.65 |
| Resistance Level | $0.49 | $2.76 |
| Average True Range (ATR) | 0.04 | 0.17 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 21.86 | 17.07 |
Price Performance
Historical ComparisonAbout NXL Nexalin Technology Inc.
Nexalin Technology Inc designs and develops neurostimulation products and bioelectronic medical technology to treat anxiety and insomnia without drugs or psychotherapy. The Company has developed the Generation 1 (Gen 1) medical device, a cranial electrotherapy stimulation (CES) device classified by the U.S. Food and Drug Administration (FDA) as a Class II device. The Company focuses on treating mental health conditions without reliance on drugs or psychotherapy. Geographically, it generates sales in the US and China, with China generating the maximum sales.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.